Dr. Reddy's Lab slumps after US Court order on Suboxone

Capital Market 

lost 9.12% to Rs 2,106 at 14:35 IST on after the company said the preliminary injunction orders issued by a against it on the launch of generic Suboxone.

The announcement was made on Saturday, 14 July 2018.

On the BSE, 2.81 lakh shares were traded in the counter so far compared with average daily volumes of 80,000 shares in the past two weeks. The stock had hit a high of Rs 2,239.40 and a low of Rs 2,071.50 so far during the day. The stock hit a 52-week high of Rs 2,788 on 24 July 2017. The stock hit a 52-week low of Rs 1,888 on 21 May 2018.

Dr. Reddy's Laboratories, along with its subsidiaries announced its intent to appeal the decision made by the US District Court for the District of in a preliminary injunction hearing with respect to further sales and commercialization of Dr. Reddy's and Sublingual Film within the The company disagrees with the court's decision, and will vigorously appeal it, said.

Dr. Reddy's had announced the receipt of the approval, on 15 June 2018 by one of its wholly owned subsidiaries, from the (USFDA) for its and Sublingual Film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg, therapeutic equivalent generic version of Suboxone (and naloxone) sublingual film, in the market.

Dr. Reddy's Laboratories' consolidated net profit fell 19.4% to Rs 272.10 crore on 0.54% fall in net sales to Rs 3534.90 crore in Q4 March 2018 over Q4 March 2017.

is an company. Through its three businesses - & Active Ingredients, Global Generics and Proprietary Products - Dr Reddy's Laboratories offers a portfolio of products and services including APls, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Mon, July 16 2018. 14:52 IST